2018-08-24T14:50:28-05:00 2017-12-31 582676261 Rogers & Company PLLC 8300 Boone Boulevard Suite 600 Vienna VA 22182 990 2017-01-01 061389829 Albert B Sabin Vaccine Institute Inc ALBE 2028428610 2175 K Street NW No 400 Washington DC 20037 Amy Finan Chief Executive Officer 2028428610 2018-08-24 1 Nicole M Prince CPA P01315245 7038930300 2018-08-24 2017 2022-09-23 18:48:47Z Amy Finan 2175 K Street NW No 400 Washington DC 20037 8119285 0 X www.sabin.org X 1994 MD To make vaccines more accessible, enable innovation and expand immunization. 9 9 47 3 0 0 14719648 8075830 19975 1225 27774 27008 31650 15222 14799047 8119285 3816018 3260072 0 0 4433036 3832495 19155 0 396723 10422006 3474104 18690215 10566671 -3891168 -2447386 17144106 15194291 1661569 2094947 15482537 13099344 X To make vaccines more accessible, enable innovation and expand immunization across the globe. 1 1 4811657 1725674 Vaccine Access and Uptake: Despite scientific advances and international support, 1.5 million people still die each year from diseases that could have been prevented by routine immunization. Sabin works with key decision makers and immunization experts at the country and global level to build resilient, sustainable national immunization programs to reach every child.It is countries' responsibility to provide effective and quality immunization for all people. Sabin partners with low- and middle-income countries to strengthen policy, secure financing and build political will for immunization. Sabin seeks to help countries establish long-term immunization financing and policy solutions that strengthen and protect immunization systems for generations to come.Sabin is an adviser, a convener and a catalyst of systemic change, bringing together researchers, national government officials and immunization specialists at all levels to support the introduction and expansion of new and under-utilized vaccines. In order to make informed decisions about vaccine introduction and implementation, countries require high-quality information and evidence. Sabin supports surveillance programs and conducts research to generate essential epidemiological data for well-designed and efficiently implemented immunization programs. By establishing and sharing best practices, we help countries evaluate and streamline vaccine introduction and scale-up.Collaboration across continents and sectors is critical to extend the benefits of immunization around the globe. Through our international scientific meetings, Sabin fosters dialogue between global health leaders, researchers and implementers to unify global efforts to accelerate access to new and under-utilized vaccines. 2410850 931234 Vaccine Knowledge & Innovation: The immunization landscape is constantly evolving. Immunization professionals are faced with the challenge of staying up-to-date on new vaccines, changing policies and recommendations, and developments in vaccine science, while the general public is inundated with information, making it difficult to discern truth from fiction.Sabin drives meaningful, well-informed conversations on emerging and established issues across the field of immunization and provides training and education on the latest in vaccine science and policy to immunization professionals, policymakers and journalists, among others.Sabin connects immunization professionals with the resources they need to overcome barriers to vaccination and improve vaccine uptake and coverage in their countries. Our scientific meetings, trainings and workshops provide professionals with the skills and tools to strengthen their countries' vaccine research capabilities, foster vaccination program resiliency and implement successful immunization campaigns.Sabin works to shape the vaccine conversation by amplifying reliable information on vaccines. We serve as a leading voice on critical issues in global immunization, including vaccine confidence, vaccine safety and global health innovation. We also work to drive more effective, accurate media coverage on vaccines by equipping journalists with the latest information on disease burden and immunization. 682199 268852 Research & Development: Sabin supports innovative technologies and approaches in vaccine research and development. For more than a decade, Sabin has collaborated with organizations around the world conducting research to develop new, low-cost vaccines for diseases impacting the world's most neglected populations. Focusing on infectious and emerging diseases that have high human impact but may lack traditional market incentives, Sabin is committed to supporting research to identify innovative solutions that will improve the lives of millions through immunization. 396865 334312 Global Network for Neglected Tropical Diseases (Global Network) Program: After more than a decade of progress, the Global Network for Neglected Tropical Diseases concluded its activities. In 2017, we provided support to the Pan American Health Organization for lymphatic filariasis control and elimination activities in Guyana in Region 4 which includes the Georgetown capital and municipality areas with a total population of 299,759 people, accounting for 56% of the total target population for mass drug administration (MDA). The project aims to achieve two key outcomes: (i) 80% program coverage for the 2018 MDA round in Region 4 (ii) achieve 65% epidemiological coverage for the 2018 MDA round in Region 4. Through the Global Network, Sabin shaped the international dialogue about NTDs. Since 2006, Sabin has brought NTDs onto the global agenda, generating political will among endemic and donor countries and working to obtain a place for NTDs in the Sustainable Development Goals. Sabin expanded treatment for NTDs across more than 80 countries by helping countries draft national plans to implement and expand treatment programs, secured more than $165 million in funding to support NTD treatment, and galvanized advocates for political and financial commitments to fight NTDs, from heads of state to the general public. Sabin's award-winning END7 campaign built a grassroots movement to garner public support for the effort to end the seven most common NTDs through advocacy, fundraising and creative digital and social media promotion. The campaign helped provide treatment for more than 50 million people in over a dozen countries by raising $1.2 million from the public to support NTD treatment programs.As part of Sabin's strategic vision to focus on vaccine R&D, access, uptake and expanding the related knowledge base, the Global Network program was closed in 2017. Sabin is proud of its decade-long contribution toward eliminating NTDs and helping to raise the profile of the millions suffering from NTDs as a cause worthy of greater attention, funding and collective response. 396865 334312 8301571 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 22 0 1 47 1 0 0 0 0 0 0 0 0 0 0 X 9 9 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD DC NY CA FL X The Organization 2028428610 2175 K Street NW No 400 Washington DC 20037 Axel Hoos Chairman 5.00 X X 0 0 0 Peter Thoren Vice Chairman 1.00 X X 0 0 0 Michael Marine Secretary 1.00 X X 0 0 0 Wendy Holman Trustee 1.00 X 0 0 0 Kenneth Kelley Trustee 1.00 X 0 0 0 Regina Rabinovich Trustee 1.00 X 0 0 0 Philip Russell Trustee 1.00 X 0 0 0 Paul Maddon Trustee 1.00 X 0 0 0 Mark Kline Trustee (through April 2017) 1.00 X 0 0 0 Paul Klotman Trustee (through April 2017) 1.00 X 0 0 0 Jordan Orange Trustee (through April 2017) 1.00 X 0 0 0 Scott Wulfe Trustee (through April 2017) 1.00 X 0 0 0 Amy Finan CEO 40.00 X 377725 0 21976 Brian Davis COO 40.00 X 247713 0 31629 Bruce Gellin President, Global Immunization 40.00 X 223324 0 7750 Peter Hotez Ex Off. Trust/Pres (through Apr 2017) 10.00 X 0 0 0 Jon Andrus Executive VP (through Feb 2017) 40.00 X 164782 0 1390 Ana Carvalho Director 40.00 X 191024 0 27752 Janet Daniels Director, Accounting 40.00 X 124883 0 15377 Denise Garrett VP, Typhoid Programs 40.00 X 206531 0 23138 Tara Hayward VP, Resource Development, Policy 40.00 X 143807 0 20971 Kathryn McGrath Director, Communications 40.00 X 113207 0 11720 1792996 0 161703 11 0 1 0 0 558899 7516931 4935 8075830 Membership dues 900099 1225 1225 1225 27008 27008 Refunds 900099 15222 15222 15222 8119285 1225 0 42230 2464852 2464852 795220 795220 1076288 713951 273057 89280 2236365 1494943 553704 187718 77394 49298 21044 7052 231360 129954 87770 13636 211088 145864 46992 18232 1476 1476 15867 15867 912803 783851 89858 39094 134919 84675 41525 8719 106419 49583 53953 2883 65721 26698 35333 3690 456925 456925 456160 433986 4141 18033 843596 827822 15774 291 278 13 338577 252600 85977 76666 19223 57443 Dues/subscriptions 50298 25843 16259 8196 Miscellaneous 14386 1454 12742 190 10566671 8301571 1868377 396723 2388225 2192495 9861579 8587760 1435208 761908 270584 18156 142853 101638 1157539 380593 29168 776946 226583 288872 2717553 2464953 72353 1563 17144106 15194291 1329780 592250 85024 4100 246765 1498597 1661569 2094947 X 1728442 2029399 13754095 11069945 15482537 13099344 17144106 15194291 X -2447386 65215 -1022 X X 0 1 X 1 0 X 19979693 18983738 17896741 14719648 8075830 79655650 19979693 18983738 17896741 14719648 8075830 79655650 37421675 42233975 24246 28526 23756 27774 27008 131310 31650 15222 46872 79833832 58450 0.52900 0.46980 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 980 980 10565691 10566671 678334 169584 0 0 1000000 1000000 1000000 678334 3678334 5517501 2692 5538 4263 980 13473 250000 250000 250000 169584 919584 1379376 1217 1897 784 3898 833755 69479 764276 323784 311114 12670 776946 Deferred rent 1203868 Deferred compensation liability 294729 1498597 X 8472524 65215 288024 353239 8119285 0 8119285 10855717 288024 1022 289046 10566671 0 10566671 Part X, Line 2: Management evaluated the Institute's tax positions and concluded that the Institute's financial statements do not include any uncertain tax positions. Part XII, Line 2d - Other Adjustments: Foreign exchange loss 1,022. 1 South Asia 0 0 Grants to recipients located in region Typhoid study sites 529850 South America 0 0 Grants to recipients located in region Dengue vaccine effectiveness study & clinical trial site 211288 Europe (Including Iceland & Greenland) 0 0 Grants to recipients located in region Vaccine and NTD control advocacy 54082 0 0 0 0 0 0 795220 0 795220 South Asia Typhoid study sites 208535 EFT South America Dengue vaccine effectiveness study 186288 EFT South Asia Typhoid study sites 175000 EFT South America Clinical trial site 25000 EFT Europe (Including Iceland & Greenland) Vaccine and NTD control advocacy 54083 EFT South Asia Typhoid study sites 146315 EFT 6 0 0 0 0 0 0 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). 1 National Foundation for the Centers for Disease Control and Prevention 600 Peachtree Street NE Suite 1000 Atlanta GA 30308 582106707 501C3 218696 Typhoid study sites Pan American Health Organization 525 23rd Street NW Washington DC 20037 237072046 1034405 NTD control and vaccine access and uptake Stanford University PO Box 44253 San Francisco CA 94144 941156365 501C3 90748 Typhoid study sites Baylor College of Medicine 1 Baylor Plaza Houston TX 77030 741613878 501C3 1121003 Vaccine development program 3 1 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). X X X X X X 1 0 0 0 0 0 0 0 0 Amy Finan CEO 340725 0 37000 0 0 0 10800 0 11176 0 399701 0 0 0 Brian Davis COO 212713 0 35000 0 0 0 8858 0 22771 0 279342 0 0 0 Bruce Gellin President, Global Immunization 223324 0 0 0 0 0 950 0 6800 0 231074 0 0 0 Jon Andrus Executive VP (through Feb 2017) 39782 0 0 0 125000 0 1103 0 287 0 166172 0 0 0 Ana Carvalho Director 191024 0 0 0 0 0 8004 0 19748 0 218776 0 0 0 Denise Garrett VP, Typhoid Programs 206531 0 0 0 0 0 8414 0 14724 0 229669 0 0 0 Tara Hayward VP, Resource Development, Policy 143807 0 0 0 0 0 6080 0 14891 0 164778 0 0 0 Part I, Line 4a Jon Andrus received severance payments in 2017 totaling $125,000. Form 990, Part III, line 2 After a significant strategic review in 2016, Sabin relaunched its advocacy focal areas as Vaccine Access & Uptake and Vaccine Knowledge & Innovation. This is not a major departure from our history; however, it does represent an intentional strategic shift moving forward and we expect this will help us achieve our vision of a world free from vaccine-preventable diseases and will help us deliver sustainable, evidence-based solutions that extend the benefits of immunization to everyone, everywhere. We are excited about the opportunities ahead. Form 990, Part III, line 3 After more than a decade of progress, the Global Network for Neglected Tropical Diseases concluded its activities. This is in alignment with Sabin's strategic vision to focus on vaccine R&D, access, uptake and expanding the related knowledge base. Sabin is proud of its decade-long contribution toward eliminating NTDs and helping to raise the profile of the millions suffering from NTDs as a cause worthy of greater attention, funding and collective response. Through the Global Network, Sabin shaped the international dialogue about NTDs. Since 2006, Sabin has brought NTDs onto the global agenda, generating political will among endemic and donor countries and working to obtain a place for NTDs in the Sustainable Development Goals. Sabin expanded treatment for NTDs across more than 80 countries by helping countries draft national plans to implement and expand treatment programs, secured more than $165 million in funding to support NTD treatment, and galvanized advocates for political and financial commitments to fight NTDs, from heads of state to the general public. Sabin's award-winning END7 campaign built a grassroots movement to garner public support for the effort to end the seven most common NTDs through advocacy, fundraising and creative digital and social media promotion. The campaign helped provide treatment for more than 50 million people in over a dozen countries by raising $1.2 million from the public to support NTD treatment programs. Form 990, Part VI, Section B, line 11b The Form 990 is prepared by an outside tax accounting firm based on independently audited financial statements. The Form 990 is then reviewed by the Director, Accounting and COO. Then the Form 990 is presented to the CEO and Finance and Audit Committee for their review and approval. Finally it is presented to the full Board of Trustees for their review before filing. Form 990, Part VI, Section B, line 12c Sabin's management, Board Chair and Governance Committee are reponsible for ensuring the conflict of interest policy is up-to-date and adhered to by the Trustees. Form 990, Part VI, Section B, line 15 Compensation of officers and/or key employees is set in consultation with input from the Board, Executive Committe or Chair as appropriate. Sabin uses a mix of data points including: independent salary surveys; comparable pay by similar organizations; compensation firms and our own internal pay scale. Form 990, Part VI, Section C, line 19 Governing documents (upon request), conflict of interest policy (upon request), and financial statement and Form 990 (Sabin's website). Form 990, Part XI, line 9: Foreign exchange loss -1,022. Form 990, Part XII, Line 2c: The Organization has a Finance and Audit Committee that assumes responsibility for oversight of the audit. This process is consistent with prior years.